Pharvaris N.V. (PHVS) vs Recursion Pharmaceuticals, Inc. (RXRX)

Pharvaris N.V. and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Pharvaris N.V. and Recursion Pharmaceuticals, Inc. are of similar size ($2.3B and $2.2B). Pharvaris N.V. has the higher net margin (0.00% vs −697.1%) and the higher return on invested capital (0.00% vs −88.5%). Across the 14 metrics below, Pharvaris N.V. leads on 7 and Recursion Pharmaceuticals, Inc. on 7.

Valuation

Metric PHVS RXRX Biotechnology median
P/E n/m n/m 10.26
P/S n/m 27.93 9.18
P/B 6.38 2.10 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m 19.78 8.98
Earnings yield (9.30%) (25.62%) (34.89%)
Free cash flow yield (7.98%) (16.50%) (24.52%)

Profitability

Metric PHVS RXRX Biotechnology median
Gross margin 0.00% 29.21% 65.16%
Operating margin 0.00% (725.44%) 0.00%
Net margin 0.00% (697.13%) 0.00%
Free cash flow margin 0.00% (460.89%) 0.00%
Return on equity (71.50%) (48.72%) (50.12%)
Return on assets (64.43%) (36.29%) (45.60%)
Return on invested capital 0.00% (88.54%) 0.00%

Growth

Metric PHVS RXRX Biotechnology median
Revenue growth (TTM) — 56.18% 6.26%
EPS growth (last fiscal year) (25.37%) 14.79% 29.88%
Revenue growth, 5-year CAGR — 79.91% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PHVS RXRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.94 5.01 4.89
Net debt to EBITDA 1.72 1.31 1.01

Dividend

Metric PHVS RXRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PHVS RXRX Biotechnology median
Market cap 2.28b 2.18b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack